Table 4.

Characteristics of the procedures with adverse events.

Patient	Adverse event	Study period	At intubation			Intubator	Intravenous access	Duration of remifentanil administration (minutes)	Cumulative dose of remifentanil (μg/kg)	Total laryngoscopic time (second)	Number of attempts
			Age* (day)	Post–menstrual age* (weeks)	Weight (g)
1	Respiratory problems	1	0–5	33	1,775	A	UVC	5	2.5	2	2
2	Chest rigidity	1	21–25	30	1,235	A	PVC	2	1	1	2
3	Respiratory problems	1	41–45	32	1,125	R	PVC	N/A	N/A	N/A	1
4	Chest rigidity	1	6–10	26	735	A	PCVC	12	6	3	2
5	Chest rigidity	1	21–25	29	885	A	PVC	1	0.5	30	3
6	Respiratory problems	1	0–5	25	750	A	UVC	10	5	7	2
7	Respiratory problems	2	26–30	33	1,570	A	PVC	10	3.67	3	2
8	Respiratory problems	2	6–10	30	1,030	R	PCVC	11	4.05	1	1
9	Laryngo–spasm	2	0–5	28	820	A	UVC	12	3	1	2
10	Chest rigidity	3	31–35	32	1,800	A	PVC	N/A	N/A	27	2
11	Chest rigidity	3	11–15	27	915	R	PCVC	3	0.6	24	3
12	Chest rigidity	3	0–5	38	3,160	A	UVC	4	1	6	2

A, neonatologist in attendance; R, pediatric resident; UVC, umbilical venous catheter; PVC, peripheral venous catheter; PCVC, percutaneous central venous catheter; N/A, not available.

^*At intubation, age is presented as a 5–day range and postmenstrual age as a 1–week range to avoid identifying patient data.